Generation, Characteristics and Clinical Trials of Ex Vivo Generated Tolerogenic Dendritic Cells.
10.3349/ymj.2018.59.7.807
- Author:
Sang Hyun KIM
1
;
Ho Hyun JUNG
;
Chong Kil LEE
Author Information
1. College of Pharmacy, Chungbuk National University, Cheongju, Korea. cklee@chungbuk.ac.kr
- Publication Type:Clinical Trial ; Review
- Keywords:
Dendritic cell;
immune tolerance;
autoimmune disease;
clinical trial;
cellular therapy
- MeSH:
Arthritis, Rheumatoid;
Autoimmune Diseases;
Crohn Disease;
Dendritic Cells*;
Humans;
Immune Tolerance;
Models, Animal;
Multiple Sclerosis;
National Institutes of Health (U.S.)
- From:Yonsei Medical Journal
2018;59(7):807-815
- CountryRepublic of Korea
- Language:English
-
Abstract:
Dendritic cells (DCs) play a key role not only in the initiation of primary immune responses, but also in the development and maintenance of immune tolerance. Numerous protocols have been developed to generate tolerogenic DCs (tolDCs) ex vivo, and the therapeutic efficacy of ex vivo-generated tolDCs has been demonstrated in autoimmune disease animal models. Based on successes in small animal models, several clinical trials have been completed or are on-going in patients with autoimmune diseases such as rheumatoid arthritis, type 1 diabetes, multiple sclerosis, and Crohn's disease. Here we describe the methods used to generate tolDCs ex vivo, and the common features shared by tolDCs. In addition, we overview five completed clinical trials with reported outcomes and summarize the tolDC-based clinical trials that are currently registered with the U.S. National Institutes of Health. Although the number of tolDC-based clinical trials is much smaller than the hundreds of clinical trials using immunogenic DCs, tolDC-based treatment of autoimmune diseases is becoming a reality, and could serve as an innovative cellular therapy in the future.
